Related by context. All words. (Click for frequent words.) 73 cell lymphomas 72 malignancies 72 leukemias 70 cancers 68 non Hodgkin lymphomas 68 glioblastoma 67 sarcomas 67 chronic lymphocytic leukemia CLL 66 neuroendocrine tumors 66 medulloblastoma 66 epithelial tumors 65 leukaemias 65 breast carcinomas 65 prostate cancers 65 DLBCL 65 solid tumors 65 follicular lymphoma 65 bladder cancers 65 adenocarcinomas 65 medulloblastomas 64 gliomas 64 myeloid 64 carcinoid tumors 64 tumors 64 CLL 64 carcinomas 64 histologies 64 grade gliomas 64 neuroblastomas 63 GISTs 63 malignancy 63 pancreatic cancers 63 basal cell carcinomas 63 osteosarcomas 63 Gleevec resistant 63 Non Hodgkin lymphoma 63 squamous cell carcinoma SCC 63 lymphoma 63 renal cell carcinoma 63 MALT lymphoma 63 myeloproliferative diseases 63 ovarian tumors 63 lung cancers 63 squamous cell carcinomas 63 Follicular lymphoma 62 hepatocellular carcinoma HCC 62 carcinoid 62 acute leukemias 62 papillary 62 BRAF gene 62 basal cell carcinoma BCC 62 glioblastoma multiforme GBM 62 epithelial cancers 62 brain metastases 62 anaplastic 62 differentiated thyroid 62 acute myelogenous leukemia AML 62 hematologic malignancies 62 lymphoma subtypes 62 neoplasms 62 pheochromocytoma 62 subtypes 62 lung tumors 62 gastric cancers 62 neuroendocrine cancers 62 carcinoma 62 thyroid cancers 61 FLT3 61 HER2 positive cancers 61 prostate pancreatic 61 imatinib Gleevec 61 astrocytomas 61 colorectal cancers 61 seminoma 61 non Hodgkin lymphoma 61 gastrointestinal stromal tumors 61 leukemia ALL 61 indolent NHL 61 Acute lymphoblastic leukemia 61 xenograft models 61 lymphoid 61 MGUS 61 breast carcinoma 61 pancreatic adenocarcinoma 61 HCV infection 61 ovarian cancers 61 Cholangiocarcinoma 61 NSCLC 61 trans retinoic acid 61 EGFR mutations 61 ependymomas 61 cell malignancies 61 prostate cancer CaP 61 leukemia AML 61 nonmelanoma skin cancers 61 astrocytoma 61 glioblastomas 61 myeloproliferative neoplasms 61 GBMs 61 lymphocytic 61 neoplastic 61 sporadic ALS 60 lymphoid tissue 60 ovarian carcinoma 60 mammary tumors 60 HNSCC 60 acute myeloid leukemia AML 60 glioma 60 Gliomas 60 CLL SLL 60 esophageal cancers 60 dasatinib 60 gastric adenocarcinoma 60 malignant lymphoma 60 PIK3CA 60 gastrointestinal cancers 60 malignant tumors 60 Glioblastoma 60 basal cell nevus syndrome 60 endometrial cancers 60 renal cell carcinomas 60 myelofibrosis polycythemia vera 60 heavily pretreated 60 cell acute lymphoblastic 60 EGFRvIII 60 HCV infections 60 Burkitt lymphoma 60 Chronic lymphocytic leukemia 60 Basal cell 60 EGFR inhibitors 60 hepatocellular carcinoma 60 pulmonary metastases 60 hypermethylation 60 T#I mutant 60 essential thrombocythemia 60 GSTP1 60 breast cancers 60 colorectal tumors 60 HPV# 60 distant metastasis 60 IGF IR 60 metastatic melanoma 60 myeloma cells 60 sarcomatoid 60 meningiomas 60 imatinib resistant 60 Leukemias 60 FGFR2 60 K ras mutations 59 Epstein Barr virus EBV 59 cell lymphoma 59 PCNSL 59 colorectal cancer CRC 59 cervical carcinoma 59 BCR ABL 59 small lymphocytic lymphoma 59 Toxicities 59 leukemia CLL 59 systemic lupus erythematosus SLE 59 oncoproteins 59 leukemias lymphomas 59 metastatic cancer 59 myelodysplastic syndrome MDS 59 serous ovarian cancer 59 squamous cell carcinoma 59 myelomas 59 imatinib resistance 59 MYCN amplification 59 adenocarcinoma 59 oncogenic 59 V#F mutation 59 childhood leukemias 59 activating mutations 59 BRAF mutations 59 melanoma 59 squamous cell lung cancer 59 hematological malignancies 59 Hedgehog pathway 59 indolent lymphoma 59 EGFR 59 liver metastases 59 chromosomal rearrangement 59 bone metastasis 59 medullary thyroid cancer 59 HDACi 59 lung adenocarcinoma 59 proto oncogene 59 premalignant 59 PCa 59 subtype 59 myeloproliferative disorders 59 metastases 59 B lymphocyte 59 gastrointestinal stromal tumors GISTs 59 cyclin E 59 lymphatic tissue 59 mesotheliomas 59 malignant pleural mesothelioma 59 myeloid cells 58 MMP inhibitors 58 hepatocellular carcinomas 58 papillary renal cell carcinoma 58 glioblastoma tumors 58 HER2 positive metastatic breast 58 lung carcinomas 58 nonsmall cell lung cancer 58 IGF 1R 58 cell carcinoma 58 lobular carcinoma 58 tyrosine kinase inhibitors 58 ADPKD 58 superficial bladder cancer 58 metastatic renal cell carcinoma 58 pediatric acute lymphoblastic 58 malignant transformation 58 CD# [002] 58 neoplasm 58 taxanes 58 TNF α 58 metastatic malignant melanoma 58 tumor subtypes 58 grade cervical intraepithelial 58 squamous cell 58 precursor lesions 58 neoplasia 58 histological subtype 58 B lymphocytes 58 Chronic Lymphocytic Leukemia CLL 58 Glioblastoma multiforme GBM 58 glioblastoma multiforme 58 metastatic colorectal 58 soft tissue sarcomas 58 prostate tumors 58 CYT# potent vascular disrupting 58 breast tumors 58 cutaneous squamous cell carcinoma 58 GBM tumors 58 MAPK pathway 58 depsipeptide 58 NF kB pathway 58 Sjögren syndrome 58 MGd 58 anemias 58 metastatic 58 HER2 positive 58 cisplatin resistant 58 prostate adenocarcinoma 58 metastatic disease 58 missense mutations 58 HbF 58 lymph node metastases 58 metastatic cancers 58 BRCA deficient 58 mycosis fungoides 58 WT1 58 gastric carcinoma 58 androgen receptor AR 58 receptor tyrosine kinase inhibitor 58 Lymphomas 58 neoplasias 58 mutated KRAS gene 58 ependymoma 58 K ras 58 MDM2 58 Kaposi sarcoma 58 Metastatic 58 pilocytic astrocytomas 58 JMML 58 pancreatic lung 58 IgA antibodies 58 chemotherapy regimens 58 Hedgehog signaling pathway 58 c MET 58 hypoxia inducible factor 58 ovarian pancreatic 58 HBeAg negative 58 lymphoproliferative disorders 58 B Cell Lymphoma 58 chronic myeloid leukemia CML 57 indolent lymphomas 57 oropharyngeal cancer 57 ALK mutations 57 cell lymphoma ALCL 57 squamous 57 imatinib Gleevec ® 57 neuroblastoma tumors 57 SOD1 57 gastric cancer 57 metastatic prostate cancer 57 metastasis 57 transgene expression 57 melanoma tumors 57 squamous cell cancers 57 esophageal adenocarcinoma 57 subependymal giant cell 57 chronic HBV infection 57 CD4 + CD# 57 urothelial carcinoma 57 HER2/neu 57 paragangliomas 57 brain tumor glioblastoma multiforme 57 cutaneous T 57 protein kinases 57 Non Hodgkin Lymphoma 57 nasopharyngeal carcinoma 57 EBV infection 57 PARP inhibition 57 lymphoid organs 57 metastatic colorectal cancer 57 hypercalcemia 57 germinal center 57 hypereosinophilic syndrome 57 cervical lesions 57 glioma cells 57 pancreatic NET 57 tumor antigen 57 gastrointestinal stromal tumor 57 colorectal gastric 57 autoimmune diseases 57 chromosomal aberrations 57 acute myeloid 57 VZV 57 hematologic disorders 57 cholangiocarcinoma 57 mutations 57 carcinoids 57 HER2 overexpression 57 Carcinoid tumors 57 PARP inhibitors 57 oligodendroglioma 57 histologic subtypes 57 cell lymphoma CTCL 57 diabetic nephropathy 57 commonly mutated genes 57 HER2 positive breast cancer 57 alkylating agent 57 KRAS wild 57 HGPIN 57 chemotherapeutic agent 57 sPLA2 57 follicular lymphomas 57 melanomas 57 pre cancerous lesions 57 lung adenocarcinomas 57 B CLL 57 Synovial sarcoma 57 familial ALS 57 hepatoma 57 lymphocytic leukemia 57 metastatic bladder 57 systemic lupus erythematosus 57 microRNA miR 57 histologic subtype 57 advanced adenomas 57 Glioblastoma Multiforme 57 pDCs 57 ErbB2 positive 57 Squamous cell 57 metastatic lesions 57 Dasatinib 57 IDH1 mutation 57 CHOP chemotherapy 57 proteasome inhibitors 57 tyrosine kinases 57 oncogenes 57 nonmetastatic 57 seminomas 57 Anaplastic 57 JAK3 57 Th1 57 molecular subtypes 57 SCCHN 57 CLL cells 57 oligodendrogliomas 57 molecular abnormalities 57 VEGF receptor 57 alveolar rhabdomyosarcoma 57 interferon pathway 57 cutaneous melanoma 57 KRAS mutant 57 relapsing remitting 57 activin 57 breast endometrial 57 Glioblastomas 57 Th2 cells 57 H. pylori infection 57 mucinous 57 esophageal tumors 57 ERBB2 57 myeloid leukemia 57 non metastatic osteosarcoma 57 epigenetic mechanisms 57 papillomas 57 synovial sarcoma 57 Cutaneous T 57 noncancerous cells 56 breast cancer subtypes 56 prostate tumor 56 p# mutations 56 endocrine tumors 56 Vidofludimus 56 testicular cancers 56 follicular lymphoma FL 56 EGFr 56 mTOR inhibitors 56 chemokine receptors 56 multiple myeloma MM 56 TNFa 56 gene rearrangements 56 xenograft tumors 56 chemotherapeutic agents 56 malignant melanoma 56 motor neuron degeneration 56 Raf MEK ERK 56 epithelial ovarian cancer 56 lymphocytes 56 bleomycin 56 colorectal cancer 56 renal carcinoma 56 TNF antagonist 56 uPAR 56 CD8 + 56 Glioblastoma multiforme 56 neuroblastoma 56 EGF receptor 56 squamous cell cancer 56 invasive ductal 56 epithelioid 56 HER2 receptor 56 Zolinza 56 Glioblastoma Multiforme GBM 56 neuroblastoma cells 56 Non Hodgkin 56 castrate resistant 56 invasive carcinoma 56 skin cancers 56 relapsed refractory 56 Smac mimetic 56 TREANDA 56 PKCi 56 chemoresistance 56 lymphoid malignancies 56 malignant lymphomas 56 intestinal polyps 56 Akt1 56 factor receptor EGFR 56 Chronic myeloid leukemia 56 Foxp3 56 associated lymphoid tissue 56 PI3K Akt 56 T#I [002] 56 Hepatocellular Carcinoma HCC 56 pancreatic colon 56 atypical hyperplasia 56 Acute myeloid leukemia 56 dasatinib Sprycel 56 oncogenic HPV types 56 Diffuse Large B 56 FGFR1 56 hematologic 56 taxane therapy 56 skeletal metastases 56 Papillary 56 Carcinoma 56 lupus nephritis 56 osteopontin 56 paraganglioma 56 oncoprotein 56 neuroendocrine carcinoma 56 HPV types 56 leiomyosarcoma 56 NKT cells 56 bendamustine 56 Chronic lymphocytic leukemia CLL 56 MEK inhibitors 56 grade glioma 56 androgen independent 56 hematologic toxicity 56 cervical intraepithelial neoplasia 56 TGF β 56 lung pancreatic 56 CDK4 56 CMV infection 56 Candida infection 56 alkylating agents 56 PTEN mutations 56 Flt3 56 parainfluenza virus 56 ovarian lung 56 tumor 56 endometrioid 56 precancerous cervical lesions 56 hepatocellular cancer 56 precancerous lesions 56 tumor cells 56 Epstein Barr virus 56 papillary RCC 56 cell lymphoma DLBCL 56 effector memory 56 vWF 56 SPINK1 56 liposomal doxorubicin 56 brain tumors 56 nodular melanoma 56 prostate cancer PCa 56 castration resistant 56 rituximab 56 miR #b [001] 56 liver fibrosis 56 erlotinib Tarceva ® 56 JAK inhibitors 56 colon cancers 56 pituitary adenomas 56 myelofibrosis 56 Valortim R 56 etoposide 56 uveal melanoma 56 tumor histology 56 metastatic gastric 56 E#F# 56 BRAF V#E 56 pan HDAC inhibitor 56 malignant fibrous histiocytoma 56 ccRCC 56 primary biliary cirrhosis 56 colon carcinoma 56 molecularly targeted 56 chronic myelogenous leukemia CML 56 Epratuzumab 56 breast pancreatic 56 leukemic stem cells 56 tumor metastases 56 tigecycline 56 autoantibodies 56 cetuximab 56 KRAS mutations 56 pneumococcal strains 56 gastric carcinogenesis 56 anaplastic astrocytoma 56 tumoral 56 Aurora kinase 56 ansamycin 56 Glioma 55 oncogenesis 55 nucleoside analogues 55 effector T 55 colorectal carcinoma 55 DFMO 55 relapsed ovarian cancer 55 hematological diseases 55 JAK2 enzyme 55 tumor xenograft models 55 colorectal carcinomas 55 primary effusion lymphoma 55 AP# [003] 55 EGFR tyrosine kinase inhibitors 55 ERK signaling 55 cell carcinomas 55 acute promyelocytic leukemia 55 metastatic melanomas 55 small molecule inhibitors 55 mycophenolate mofetil 55 Bortezomib 55 osteosarcoma 55 hedgehog pathway 55 malignant gliomas 55 receptor subtype 55 kidney urologic 55 CaP 55 LRP5 55 Plasmodium falciparum 55 BRAF mutation 55 micrometastases 55 colony stimulating factors 55 mtDNA mutations 55 breast ovarian 55 pDC 55 nonmelanoma skin cancer 55 eosinophils 55 immune modulators 55 colorectal lung 55 vWD 55 c myc 55 pancreatic prostate 55 EGFR mutation 55 lymphocyte 55 KRAS oncogene 55 metastatic neuroendocrine tumors 55 Adenocarcinoma 55 Acute myelogenous leukemia 55 topotecan 55 IL 1ß 55 frontotemporal dementia 55 stage IIIB 55 acute GvHD 55 TTR amyloidosis 55 miRNA genes 55 anti leukemic 55 Irinotecan 55 lymphoid cells 55 acute lymphoblastic 55 suppressor cells 55 immunocompetent 55 sarcoma 55 gastrointestinal stromal tumor GIST 55 basal cell cancers 55 NF1 55 ductal cancer 55 advanced adenoma 55 IGFBP 3 55 antibody responses 55 basal cell carcinoma 55 ara C 55 Sezary syndrome 55 Squamous 55 TTR gene 55 Philadelphia Chromosome Positive 55 cisplatin 55 Mantle Cell Lymphoma 55 neurodegenerative disorder 55 hTERT 55 interferon IFN 55 node metastases 55 tumor recurrence 55 mycobacterium 55 mesothelin 55 situ LCIS 55 JAK2 55 Cancers 55 adenomas 55 genetic determinants 55 Stat3 55 GNAQ 55 HDAC 55 CTCL 55 hepatitis C HCV 55 Waldenstrom macroglobulinemia 55 Malignant Melanoma 55 microRNA expression 55 ErbB2 55 premalignant lesions 55 tumor suppressor genes 55 Tregs 55 Carboplatin 55 ADVEXIN 55 antiproliferative effects 55 KRAS gene 55 metastatic prostate 55 HBeAg positive 55 VEGF inhibitors 55 ADAM# 55 PDGFR 55 Tumor Necrosis Factor 55 histone deacetylase HDAC inhibitor 55 chronic eosinophilic leukemia 55 renal tumors 55 inflammatory bowel diseases 55 Leydig cell 55 Follicular Lymphoma 55 trans retinoic acid ATRA 55 Hematologic 55 cardiac toxicity 55 liver metastasis 55 hormone refractory 55 B7 H3 55 Tumors 55 PARP inhibitor 55 recurrent glioblastoma multiforme 55 EGF receptors 55 mutational status 55 secondary hyperparathyroidism 55 interleukin IL -# 55 radiosensitivity 55 castrate resistant prostate cancer 55 HLA DR 55 pre cancerous 55 chronic lymphocytic leukemia 55 induce apoptosis 55 embryonal rhabdomyosarcoma 55 azacytidine 55 B Raf 55 Helicobacter pylori infection 55 seliciclib 55 ovarian breast 55 Epidermal Growth Factor Receptor 55 lipid abnormalities 55 Enzastaurin 55 esophageal squamous cell carcinoma 55 basal cell 55 thalidomide Thalomid 55 macroalbuminuria 55 Tumours 55 hematopoietic cancers 55 EGFR mutant 55 TNF blocker therapy 55 antitumor 55 genomic alterations 55 GSK3 55 gefitinib Iressa 55 apoptotic pathway 55 familial amyloidotic polyneuropathy FAP 55 myeloperoxidase 55 oral squamous cell 55 miR #a [002] 55 antitumor effect 55 herpesviruses 55 adenoma 55 castration resistant prostate cancer 55 malignant lesions 55 recurrent glioblastoma 55 BRAF protein 55 Clusterin 55 endostatin 55 Wnt signaling pathway 55 mediated immunity 55 somatic mutations 55 HCV genotypes 55 kinase inhibition 55 HPVs 55 leukaemic stem cells 55 Non Hodgkins lymphoma 55 demonstrated antitumor activity 55 TMEM#B 55 toxicities 55 IL 1beta 55 lymphomas leukemias 55 febrile neutropenia 55 Hashimoto thyroiditis 55 Ceflatonin 55 meningioma 55 axillary lymph nodes 55 HGS ETR1 54 EGFR HER2 54 anti angiogenic therapy 54 TRAIL induced apoptosis 54 SSc patients 54 malignant brain 54 PC3 cells 54 endometrial hyperplasia 54 pancreatic neuroendocrine tumors 54 Hodgkin lymphoma HL 54 chloride secretion 54 plasma kallikrein 54 squamous cell skin 54 standard chemotherapy regimens 54 imatinib 54 hematopoietic malignancies 54 glomerulonephritis 54 histone deacetylase inhibitor 54 distant metastases 54 cutaneous T cell 54 T lymphocytes 54 Abeta# 54 candidemia 54 DMARDs 54 lymphoma CTCL 54 idiopathic myelofibrosis 54 erythropoiesis 54 SSc 54 mesenchymal cell 54 histone deacetylase inhibitors 54 glycosylated 54 serotonin receptor 54 Factor Receptor 54 hematological cancers 54 Osteosarcoma 54 genomic instability 54 NOMID 54 ALK inhibitors 54 proteasome inhibitor 54 herpes viruses 54 tumor shrinkage 54 Fludarabine 54 PNET 54 Medullary thyroid cancer 54 common hematologic malignancy 54 MTHFR 54 effector function 54 c MYC 54 Vorinostat 54 CIN2 + 54 KRAS mutation 54 histological subtypes 54 neoplastic lesions 54 untreated celiac disease 54 testicular germ cell 54 carcinoid cancer 54 CDDO Im 54 Th# cells 54 tumors GIST 54 HER2 positive tumors 54 mitochondrial dysfunction 54 Herpes simplex virus 54 IGFBP 54 adenomatous polyps 54 Upregulation 54 oncogenic transformation 54 promoter methylation 54 cytotoxic chemotherapy 54 metastatic tumors 54 Myelofibrosis 54 hematologic cancers 54 osteoclast activity 54 gene mutations 54 pomalidomide 54 enzastaurin 54 Wilms tumor 54 fibrosis 54 gastrointestinal stromal tumors GIST 54 Janus kinase 54 metastatic malignant 54 overexpressed 54 recurrent ovarian cancer 54 tanespimycin 54 STK# [002] 54 panobinostat 54 RSV infection 54 germline mutations 54 chemopreventive agents 54 metastatic RCC 54 isotypes 54 xenografts 54 acute promyelocytic leukemia APL 54 lung metastases 54 uterine cancers 54 enteroviruses 54 Acute Myeloid Leukemia AML 54 poly ADP ribose polymerase 54 anticancer agents 54 nonalcoholic steatohepatitis NASH 54 paclitaxel Taxol 54 Chronic Myelogenous Leukemia CML 54 Cryptococcus neoformans 54 mRCC 54 rhabdomyosarcoma 54 invasive breast cancer 54 juvenile idiopathic arthritis JIA 54 NPM1 54 Azedra 54 clade B 54 CD# antigen 54 Treg cell 54 NNRTI resistance 54 recurrent NSCLC 54 immunotherapies 54 interferons 54 mCRC patients 54 hamartomas 54 PC# cells 54 C. albicans 54 thyroid tumors 54 GPx 54 ALN TTR 54 NRTI resistance 54 IgG antibodies 54 tumor progression 54 neurofibromas 54 cervical breast 54 Li Fraumeni 54 multidrug resistance 54 Proxinium TM 54 abnormal proteins 54 lymphocytosis 54 micro RNAs 54 simplex virus 54 erlotinib Tarceva 54 hepatic fibrosis 54 Hodgkin lymphomas 54 pancreatic tumors 54 miRNAs 54 angiosarcoma 54 malignant pheochromocytoma 54 pleomorphic 54 prostate carcinoma 54 metachronous 54 TNF inhibitors 54 AAV2 54 nasopharyngeal cancer 54 dasatinib Sprycel ® 54 pemphigus vulgaris 54 antitumor activity 54 P. aeruginosa 54 Vidaza ® 54 recurrent glioblastoma multiforme GBM 54 cell lung cancer 54 Hurthle cell 54 malignant melanomas 54 lobular breast cancer 54 Acute Lymphoblastic Leukemia 54 VUR 54 bevacizumab Avastin ® 54 Peutz Jeghers syndrome 54 ALCL 54 malignant pancreatic 54 pre malignant lesions 54 transgenic rats 54 YONDELIS 54 basal cell skin 54 CD# mAb 54 axitinib 54 pegylated liposomal doxorubicin 54 actinic keratosis 54 leukemic cells 54 anticancer therapy 54 hA# 54 haematologic 54 T2DM 54 N Myc 54 imetelstat 54 acute myeloid leukemia 54 decitabine 54 bowel cancers 54 immunoreactivity 54 retinoids 54 myeloproliferative disorder 54 GIST 54 nanomolar 54 retinoic acid receptor 54 BRCA1 BRCA2 54 targeting CD# 54 Pemetrexed 54 renal toxicity 54 antigen CD# 54 Aurora kinases 54 Doxil ® 54 oral JAK1 54 syngeneic 54 Symadex 54 papillary thyroid carcinoma 54 chromosomal translocation 54 chemotherapy induced neutropenia 54 monoclonal anti 54 Estrogen Receptor 54 cerebrospinal fluid CSF 54 luteinizing hormone releasing 54 pleural mesothelioma 54 malignant phenotype 54 interferon alfa 54 adrenocortical cancer 54 AEG# 54 poorer prognosis 54 cellular pathways 54 potent inhibition 54 chitinase 54 autoantibody 54 RASSF1A 54 receptor inhibitor 54 Lymphoma 54 malignant growths 54 ductal breast cancer 54 interleukins 54 proliferative diabetic retinopathy 54 nonmelanoma 54 kinases 54 BRCA mutations 54 vulvar intraepithelial neoplasia 54 azacitidine 54 polycythemia vera 54 invasive fungal infections 54 grade serous ovarian 54 thymoma 54 heavily pretreated patients 54 allergic asthma 54 IL 1β 54 T#I mutation 54 acute lymphoid leukemia 54 p#INK#a 54 essential thrombocythemia ET 54 Aß 54 refractory gout 54 Helicobacter 54 p# mitogen activated 54 HPV infection 54 selective inhibitor 54 lymphoblastic leukemia 54 invasive ductal carcinoma 54 COX2 54 goblet cells 54 FOLFIRI alone 54 homozygotes 54 cytotoxicity 54 Squamous cell carcinomas 54 polymerase inhibitors 54 cyclin dependent kinases 54 atherosclerotic lesions 54 Vicinium TM 54 NSCLC tumors 54 glycolipids 54 precancers 54 Th1 cells 53 Kit CD# positive 53 fusion protein 53 breast cancer metastasis 53 chemoresistant 53 curable cancers 53 Sudhir Agrawal D.Phil 53 estrogen receptor negative 53 vimentin 53 lymphocyte activation